Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Some patients with diffuse large B-cell lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis. Their outcomes in the rituximab era are not fully defined. Using a prospectively followed cohort of 1324 newly diagnosed DLBCL patients treated with immunochemotherapy, we defined the p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Wang, Yucai, Link, Brian K., Witzig, Thomas E., Maurer, Matthew J., Allmer, Cristine, King, Rebecca L., Feldman, Andrew L., Habermann, Thomas M., Ansell, Stephen M., Slager, Susan L., Cerhan, James R., Nowakowski, Grzegorz S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888139/
https://ncbi.nlm.nih.gov/pubmed/31350266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000858
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados